Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biden’s Pandemic Preparedness Plan Targets Vaccine Design, FDA Regulatory Approaches

Executive Summary

Administration proposal is long on ambition, short on details; goals are to confront future pandemics, including improving vaccines and therapeutics, manufacturing capacity and supply chains.

You may also be interested in...



Biden’s ‘Test To Treat’ Plan Will Include Merck And Pfizer COVID Pills, But Only One Gets Public Thanks

Hundreds of pharmacy-based clinics and community health centers will offer free COVID testing and treatment. Government has secured 20 million doses of Pfizer’s Paxlovid, deemed to be a ‘game changer,’ though Merck’s molnupiravir is expected to be important in long-term care facilities.

Biden vs. Pharma: ‘You Come For The King…’

The president’s state of the union address comes after a year of mostly disappointing efforts for the administration on COVID and drug pricing.

ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment

Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS144903

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel